false
0001610820
A1
0001610820
2024-09-09
2024-09-09
0001610820
BCTX:CommonSharesNoParValueMember
2024-09-09
2024-09-09
0001610820
BCTX:WarrantsToPurchaseCommonSharesNoParValueMember
2024-09-09
2024-09-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 9, 2024
BRIACELL
THERAPEUTICS CORP.
(Exact
name of registrant as specified in its charter)
British
Columbia |
|
47-1099599 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(I.R.S.
Employer
Identification
No.) |
|
|
|
Suite
300 - 235 15th Street
West
Vancouver, BC V7T 2X1 |
|
V7T
2X1 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(604)
921-1810
(Registrant’s
telephone number, including area code)
Commission
File No. 001-40101
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered under Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Shares, no par value |
|
BCTX |
|
The
Nasdaq Stock Market LLC |
Warrants
to purchase common shares, no par value |
|
BCTXW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
September 9, 2024, BriaCell Therapeutics Corp. (the “Company”) issued a press release announcing a poster presentation at
the Society for Immunotherapy of Cancer 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated by reference herein.
On
September 10, 2024, the Company issued a press release announcing positive outcomes from its pre-investigational new drug meeting with
the U.S. Food and Drug Administration. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference
herein.
On
September 11, 2024, the Company issued a press release announcing positive overall survival data in a six-month update of its Phase 2
clinical study of Bria-IMT™ in combination with an immune check point inhibitor in late stage metastatic breast cancer. A copy
of the press release is attached hereto as Exhibit 99.3 and is incorporated by reference herein.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BRIACELL
THERAPEUTICS CORP. |
|
|
|
/s/
William V. Williams |
September
11, 2024 |
William
V. Williams |
|
President
and Chief Executive Officer |
Exhibit
99.1
BriaCell
Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA
and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to
transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November
6-10, 2024, in Houston, TX.
“We
are thrilled to be invited to present our data at this prestigious conference,” stated Miguel Lopez-Lago, PhD, BriaCell’s
Chief Scientific Officer. “We look forward to continuing our investigations of novel targeted immunotherapy candidates in clinical
studies with the goal of making a positive contribution to the lives of breast cancer and prostate cancer patients.”
The
details about the presentation and session Information are as follows:
Location:
Exhibit Halls A B George R. Brown Convention Center, Houston, TX
Date and Time: Friday, Nov. 8, 2024, 9:00 am -7:00 pm CST
Following
the presentation, a copy of the poster will be posted on https://briacell.com/scientific-publications/.
About
BriaCell Therapeutics Corp.
BriaCell
is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available
at https://briacell.com/.
Safe
Harbor
This
press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in this press release are forward-looking statements.
Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,”
“intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “aim,” “should,” “will,”
“would,” or the negative of these words or other similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements, including those about BriaCell continuing its clinical study investigations of its
novel targeted immunotherapy candidates, are based on BriaCell’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are
based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion
and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under
“Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and
the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca
and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Contact
Information
Company
Contact:
William
V. Williams, MD
President
& CEO
1-888-485-6340
info@briacell.com
Media
Relations:
Jules
Abraham
CORE
IR
julesa@coreir.com
Investor
Relations Contact:
CORE
IR
investors@briacell.com
![](https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/ex99-1_001.jpg)
Exhibit
99.2
![](https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/ex99-2_001.jpg)
BriaCell
Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
|
● |
BriaCell
has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™
in prostate cancer |
|
|
|
|
● |
The
meeting provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+™ |
PHILADELPHIA
and VANCOUVER, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to
transform cancer care, is pleased to announce that it has received positive feedback from its Pre-IND meeting with the U.S. Food and
Drug Administration (FDA), which is a step forward to opening an IND to conduct a Phase 1/2 study of its personalized off-the-shelf immunotherapy,
Bria-PROS+™, in advanced prostate cancer.
“We
were truly impressed by the FDA team of experts’ keen interest in Bria-PROS+™ as a potential novel personalized approach
for advanced prostate cancer,” stated Dr. William V. Williams, BriaCell’s President and CEO. “Despite numerous approved
drugs, prostate cancer remains the second-leading cause of cancer death in American men. We view the FDA’s positive feedback as
a major step forward in the clinical development of our Bria-PROS+™ and in our efforts to bring hope to patients and families suffering
from this deadly disease.”
As
a result of the Pre-IND meeting, FDA waived the animal toxicology and animal pharmacokinetic (PK) studies requirement for opening the
IND, greatly simplifying the development pathway for Bria-PROS+™. Other areas of discussion included BriaCell’s plan to initiate
the Phase 1/2 study pending completion of standard manufacturing and testing requirements. These interactions also inform the further
development of the proprietary Bria-OTS+™ platform as the company pursues the development of Bria-BRES+™, Bria-LUNG+™
and Bria-MEL+™, for breast cancer, lung cancer and melanoma, respectively.
BriaCell
is currently evaluating its personalized immunotherapy Bria-BRES™ in a phase 1/2a study in metastatic breast cancer (ClinicalTrials.gov
NCT06471673).
About
BriaCell Therapeutics Corp.
BriaCell
is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available
at https://briacell.com/.
Safe
Harbor
This
press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,”
“could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements, including statements about the Company’s belief of the therapeutic
potential of Bria-PROS+™’s as a safe and effective treatment for prostate cancer patients, are based on BriaCell’s
current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and
uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s
Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and
under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities
and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca
and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Contact
Information
Company
Contact:
William
V. Williams, MD
President
& CEO
1-888-485-6340
info@briacell.com
Media
Relations:
Jules
Abraham
CORE
IR
julesa@coreir.com
Investor
Relations Contact:
CORE
IR
investors@briacell.com
Exhibit
99.3
![](https://www.sec.gov/Archives/edgar/data/1610820/000149315224035737/ex99-3_001.jpg)
BriaCell
Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
● | Median
overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination
with immune checkpoint inhibitor |
● | OS
of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the
literature |
● | Ongoing
Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population |
● | No
drug related discontinuations to date |
PHILADELPHIA,
PA and VANCOUVER, BC, September 11, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”
or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is
pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check
point inhibitor (CPI) in late stage metastatic breast cancer.
Median
overall survival of 15.6 months is reported in BriaCell’s most recent patients (treated since 2022) vs. 6.7-9.3 months for similar
patients reported in the literature (see table below). These patients are being treated with the same Bria-IMT™ formulation currently
being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612)
and represent patients enrolled post-COVID when full study activities resumed.
This
represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December
2023.
“Overall
survival in patients with heavily pre-treated metastatic breast cancer is very poor,” stated Sara A. Hurvitz, MD, Professor of
Medicine, Fred Hutch Cancer Center and University of Washington and BriaCell medical advisory board member. “The BriaCell early
data is quite encouraging from both efficacy and tolerability standpoints.”
“We
wanted to look at the Phase 2 data of those patients who most closely resemble the patients being treated in our ongoing phase 3 study
and compare them to similar patients in the literature,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The
nearly two-fold overall survival benefit we are seeing with the Bria-IMT™ regimen, together with the similar previously reported
approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT™
could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients. We look forward to further clinical
development of Bria-IMT™ with the goal of establishing it as a new standard of care for patients with metastatic breast cancer.”
“The
Bria-IMT™ regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated
metastatic breast cancer patients who have failed numerous prior treatments including immune check point inhibitors and antibody drug
conjugates,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “These survival and clinical benefit
data support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™
and drive the ongoing pivotal study of our combination regimen in the treatment of metastatic breast cancer.”
The
Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6) who were treated
with the Bria-IMT™ regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation
and 25 of these were treated post-COVID when full study activities resumed. This data represents an additional six months of follow-up
of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023.
Table
1. Comparative Median Overall Survival (OS) and Progression-Free Survival (PFS) in Similar Patients (Interim Analysis Using Kaplan-Meier
Estimate)
Study |
|
Prior
Lines
of Therapy
(median,
range) |
|
Number
of
Patients |
|
OS
(months) |
|
PFS
(months) |
BriaCell’s
Phase 2 study patients who received pivotal Phase 3 study formulation (since 2022) |
|
5.5
(2-13) |
|
25 |
|
15.6 |
|
4.1 |
BriaCell’s
Phase 2 study patients who received pivotal Phase 3 study formulation (total) |
|
6
(2-13) |
|
37 |
|
13.4 |
|
3.9 |
Bardia,
A. et. al. 1 (TNBC) |
|
4
(2-14) |
|
262 |
|
6.9 |
|
1.7 |
Tripathy
D. et. al. 2 (Brain metastases) |
|
≥4
in 91% |
|
178 |
|
7.5-7.8 |
|
1.9-2.8 |
O’Shaughnessy
J. et. al. 3
non-TNBC
at initial diagnosis |
|
5
(2-14) |
|
76 |
|
6.7 |
|
2.3 |
O’Shaughnessy
J. et. al. 3
TNBC
at initial diagnosis |
|
4
(2-10) |
|
157 |
|
6.9 |
|
1.6 |
Cortes
et. al. 4 |
|
4
(0-13) |
|
594 |
|
9.1-9.3 |
|
1.9-2.5 |
References
1. | Bardia
A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic
Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor
Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744.
doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473. |
2. | Tripathy
D, et al. Treatment with etirinotecan pegol for patients with metastatic breast cancer and
brain metastases: final results from the phase 3 ATTAIN randomized clinical trial. JAMA Oncol.
2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514. |
3. | O’Shaughnessy
J et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis
in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative
breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7.
Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646. |
4. | Cortes
J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez
N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román
García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine
versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051. PMID: 29481630. |
About
BriaCell Therapeutics Corp.
BriaCell
is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available
at https://briacell.com/.
Safe
Harbor
This
press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,”
“could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,”
“will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements, including statements about: the impact of Bria-IMT™ on patients with
metastatic breast cancer; BriaCell’s further clinical development of Bria-IMT™; and the efficacy of immune check point inhibitors,
are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult
to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.
These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s
most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent
Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities
regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles
on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are
made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable
law.
Neither
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Contact
Information
Company
Contact:
William
V. Williams, MD
President
& CEO
1-888-485-6340
info@briacell.com
Media
Relations:
Jules
Abraham
CORE
IR
julesa@coreir.com
Investor
Relations Contact:
CORE
IR
investors@briacell.com
v3.24.2.u1
Cover
|
Sep. 09, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 09, 2024
|
Entity File Number |
001-40101
|
Entity Registrant Name |
BRIACELL
THERAPEUTICS CORP.
|
Entity Central Index Key |
0001610820
|
Entity Tax Identification Number |
47-1099599
|
Entity Incorporation, State or Country Code |
A1
|
Entity Address, Address Line One |
Suite
300 - 235 15th Street
|
Entity Address, City or Town |
West
Vancouver
|
Entity Address, State or Province |
BC
|
Entity Address, Postal Zip Code |
V7T
2X1
|
City Area Code |
(604)
|
Local Phone Number |
921-1810
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Shares, no par value |
|
Title of 12(b) Security |
Common
Shares, no par value
|
Trading Symbol |
BCTX
|
Security Exchange Name |
NASDAQ
|
Warrants to purchase common shares, no par value |
|
Title of 12(b) Security |
Warrants
to purchase common shares, no par value
|
Trading Symbol |
BCTXW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BCTX_CommonSharesNoParValueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BCTX_WarrantsToPurchaseCommonSharesNoParValueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Sep 2023 to Sep 2024